

Vivinex™ iSert®

VIVINEX™ OFFERS CLARITY OF VISION




Vivinex™ preloaded in the **Vivinex™ iSert®** injector
provides **outstanding delivery consistency**

Vivinex™ iSert®

Designed to provide outstanding optical quality, Vivinex™ offers clarity of vision for patients suffering from cataract. Product quality, dedication and attention to detail are deeply rooted in our Japanese heritage and with 2 million lenses implanted worldwide, surgeons' trust in Vivinex™ is proven.

- Glistening-free hydrophobic acrylic IOL material^[1,2]
- Proprietary aspheric optic design for improved image quality^[3]
- Active oxygen processing treatment, a smooth surface and square optic edge to reduce PCO^[1,4,5,6,7,8,9,10]

More than
2,000,000
Vivinex™
IOLs implanted




*Hydrophobic acrylic Vivinex™
with UV-filter (Model XC1),
with UV- and blue light filter
(Model XY1)*


Glistening-free hydrophobic IOL material

A randomised clinical study was conducted to independently compare Vivinex™ (Model XY1) with Alcon AcrySof IQ SN60WF*. Final results show glistening formation after 3-years post-op.^[1]

Clinical comparison of glistenings^[11]



In vitro glistening formation at 14x magnification^[2]



Vivinex™ XY1 (HOYA)

Grade 0 (glistening-free),
based on Miyata et al.^[12]
with 11.6 ± 5.7 MV/mm²




AcrySof IQ SN60WF (Alcon)*

Grade 2-3,
based on Miyata et al.^[12]
with 264.4 ± 110.3 MV/mm²

Proprietary aspheric optic design for improved image quality

Hoya's optic contains two distinct aspheric elements that are tuned to avoid typical induction of coma associated with traditional aspheric optics. These optical zones in the Vivinex™ IOL induce positive and negative coma to compensate for the loss of image quality caused by the natural misalignment between visual and optical axis in the eye. The optic as a whole is designed to cancel out coma, providing patients with improved off-axis image quality versus traditional negative aspheric IOL designs.^[3]




This image is for illustrative purposes only and may not be an exact representation of the product.

Reduced coma caused by off-axis alignment


In the presence of decentration Vivinex™ minimises coma when compared with other aspheric IOLs at 4.0 mm pupil diameter.^[3]

Studies have shown that the mean decentration of an IOL following cataract surgery is 0.4 ± 0.2 mm with a range up to 1.7 mm.^[13]

■ Vivinex™ XY1 (HOYA)
■ Tecnis 1P ZCB00V (J&J)*
■ AcrySof IQ SN60WF (Alcon)*



Vivinex™ IOL design



Active oxygen processing treatment, a smooth surface and square optic edge to reduce PCO

Vivinex™ is made from a novel hydrophobic acrylic, using a proprietary manufacturing process that includes a unique, active oxygen posterior surface treatment. This as well as its square edge design and one of the smoothest and most regular IOL surfaces has been shown to provide a low incidence of PCO in several studies.^[1,4,5,6,7,8,9,10]

Reduction of PCO



	Vivinex™ XY1 (HOYA)		AcrySof IQ SN60WF (Alcon)*	
Objective (EPCO score)	0.12 ± 0.19 n = 57	P = .026	0.24 ± 0.46 n = 57	In a randomized multi-center trial, Vivinex™ demonstrated significantly lower objective and subjective PCO scores versus AcrySof IQ* after 3-years. ^[11]
Subjective (slit lamp score)	0.30 ± 0.55 n = 67	P = .044	0.48 ± 0.84 n = 67	
Nd:YAG rate	0.0% n = 67	P = 1.00	1.5% n = 67	
Objective (AQUA score)	0.9 ± 0.8 n = 64	P < .001	1.4 ± 1.1 n = 62	In a randomized single-center trial, Vivinex™ demonstrated significantly lower objective and subjective PCO scores compared to AcrySof IQ* after 3-years. ^[4]
Subjective (slit lamp score)	1.4 ± 1.4 n = 64	P = .001	2.3 ± 2.0 n = 62	
Nd:YAG rate	11.4% n = 70	P = .23	18.6% n = 70	

These results confirm low occurrence of PCO in both IOL groups and significantly lower PCO incidence with Vivinex™ compared to AcrySof IQ*.

More than 9 million HOYA preloaded IOLs implanted worldwide

Vivinex™ iSert® provides outstanding delivery consistency and offers the following features:^[16,17]

- Injector tip outer diameter of 1.70 mm
- Uni-directional slider
- Screw injector with fixed grip



Step A

Infuse the OVD into the injector through the infusion port. Fill up the area indicated by dotted lines.



Step B

Press the release tabs, lift up and remove the cover from the case.



Step C

Hold body with thumb and push the slider slowly forward until it stops. Remove the injector from the case.




Step D

Carefully insert the injector tip into the eye through the incision, keeping the slit of the tip in a downward position. Slowly rotate the injector knob clockwise, to inject the lens into the capsular bag.

The handling shown above illustrates in summary the product application and does not replace the Instruction For Use.

Technical characteristics



Vivinex™ iSert®				
Model name	XC1 XY1			
Optic design	Aspheric design with square, thin and textured optic edge			
Optic & haptic materials	Hydrophobic acrylic Vivinex™ with UV-filter (Model XC1), with UV- and blue light filter (Model XY1)			
Haptic design	Textured-rough haptic surface			
Diameter (optic/OAL)	6.00 mm / 13.00 mm			
Power	+6.00 to +30.00 D (in 0.50 D increments)			
Nominal A-constant**	118.9			
Optimized constants***	Haigis	a ₀ = -0.8028	a ₁ = 0.2133	a ₂ = 0.2245
	Hoffer Q	pACD = 5.697		
	Holladay 1	sf = 1.934		
	SRK/T	A = 119.198		
Injector	Vivinex™ iSert® preloaded			
Front injector tip outer diameter	1.70 mm			
Recommended incision size	2.20 mm			

** The A-constant is presented as a starting point for the lens power calculation. When calculating the exact lens power, it is recommended that calculations be performed individually, based on the equipment used and operating surgeon's own experience.

*** These optimized constants for the calculation of intraocular lens power published by IOLCon on their website: <https://iolcon.org> are calculated from 1,475 clinical results for Vivinex™ model XY1/XC1 as of September 24, 2021. These constants are based on actual surgical data and are provided by IOLCon as a starting point for individual constant optimizations. The information available on the website is based on data originating from other users and not by HOYA Surgical Optics ("HSO"). HSO therefore does not warrant the correctness, completeness and currentness of the contents on the said website.

- 1 HOYA data on file. DoF-CTM-21-002, HOYA Medical Singapore Pte. Ltd, 2021
- 2 Tandogan, T. et al. (2021): In-vitro glistening formation in six different foldable hydrophobic intraocular lenses. In: BMC Ophthalmol 21, 126
- 3 Pérez-Merino, P.; Marcos, S. (2018): Effect of intraocular lens decentration on image quality tested in a custom model eye. In: Journal of cataract and refractive surgery 44 (7), p. 889–896.
- 4 Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224–231.
- 5 Nanavaty, M. et al. (2019): Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), p. 847–853.
- 6 Giacinto, C. et al. (2019): Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. In: Journal of cataract and refractive surgery 45 (9), p. 1330–1334.
- 7 Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490–1497.
- 8 Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040.
- 9 Farukhi, A. et al. (2015): Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. In: Journal of cataract and refractive surgery 41 (5), p. 1081–1087.
- 10 Eldred, J. et al. (2019): An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 (1), p. 113–122.
- 11 Christiansen, G. et al. (2001): Glistenings in the AcrySof intraocular lens: pilot study. In: Journal of cataract and refractive surgery 27 (5), p. 728–733.
- 12 Miyata, A. et al. (2001): Clinical and experimental observation of glistening in acrylic intraocular lenses. In: Japanese journal of ophthalmology 45 (6), p. 564–569.
- 13 Harrer, A. et al. (2017): Variability in angle κ and its influence on higher-order aberrations in pseudophakic eyes. In: Journal of cataract and refractive surgery 43 (8), p. 1015–1019.
- 14 Meacock, W. et al. (2002): The effect of texturing the intraocular lens edge on postoperative glare symptoms: a randomized, prospective, double-masked study. In: Archives of ophthalmology (Chicago, Ill. : 1960) 120 (10), p. 1294–1298.
- 15 Das, K. et al. (2019): In vitro and schematic model eye assessment of glare or positive dysphotopsia-type photic phenomena: Comparison of a new material IOL to other monofocal IOLs. In: Journal of cataract and refractive surgery 45 (2), p. 219–227.
- 16 Oshika, T.; Wolfe, P. (2019): In vitro comparison of delivery performance of 4 preloaded intraocular lens injector systems for corneal and sclerocorneal incisions. In: Journal of cataract and refractive surgery 45 (6), p. 840–846.
- 17 Haldipurkar, S. et al. (2020): Incision size changes after cataract surgery with intraocular lens implantation: comparison of 2 preloaded IOL implantation injectors. In: Journal of cataract and refractive surgery 46 (2), p. 222–227.

* Third-party trademarks used herein are the property of their respective owners.

Information contained is intended for health care professionals. For a full list of indications and contra indications please refer to the Instructions For Use. Some of the products and/or specific features as well as the procedures featured in this document may not be approved in your country and thus may not be available there. Design and specifications are subject to change without prior notice as a result of ongoing technical development. Please contact our regional representative regarding individual availability in your country. HOYA, Vivinex and iSert are trademarks of the HOYA Corporation or its affiliates.

©2021 HOYA Medical Singapore Pte. Ltd. All rights reserved.



HOYA Medical Singapore Pte. Ltd | 455A Jalan Ahmad Ibrahim | Singapore 639939



HOYA Surgical Optics GmbH | De-Saint-Exupéry-Straße 10 | 60549 Frankfurt am Main | Germany
Hotline DE: Tel. +49 (0)800 664 2 664 | Fax +49 (0)800 774 2 774

hoyasurgicaloptics.com



2021-09-22_HSOE_XC1_XY1_BR_EN

HOYA
SURGICAL OPTICS